Literature DB >> 8890402

Inhibitors of stone formation.

E M Worcester1.   

Abstract

Urine contains substances that inhibit the nucleation, growth, aggregation, and cell attachment of crystals. These may function to protect the kidney against the possibility of pathological calcification in tubular fluid and urine, which are generally supersaturated with respect to calcium salts, thereby preventing stone formation. Effects on calcium oxalate are the best studied, and most of the inhibitory activity resides in macromolecules such as glycoproteins and glycosaminoglycans. Inhibitory proteins found in urine include nephrocalcin, Tamm-Horsfall protein, uropontin, crystal matrix protein (F1 prothrombin fragment), and uronic acid-rich protein (bikunin). Most of the molecules are anionic, with many acidic amino acid residues, frequently contain post-translational modifications such as phosphorylation and glycosylation, and appear to exert their effects by binding to calcium oxalate surface. The specific structural motifs that favor crystal binding and inhibition are not yet known. A number of the proteins are made by renal epithelial cells, whereas others gain access to the urine by glomerular filtration. In a number of cases, abnormalities of protein structure or function have been found in stone formers. It is not yet known what proportion of stone formers have an abnormality of inhibitor function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890402

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  12 in total

1.  Abrogation of store-operated Ca2+ entry protects against crystal-induced ER stress in human proximal tubular cells.

Authors:  Farai C Gombedza; Samuel Shin; Yianni L Kanaras; Bidhan C Bandyopadhyay
Journal:  Cell Death Discov       Date:  2019-08-05

2.  Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein.

Authors:  Yan Liu; Lan Mo; David S Goldfarb; Andrew P Evan; Fengxia Liang; Saeed R Khan; John C Lieske; Xue-Ru Wu
Journal:  Am J Physiol Renal Physiol       Date:  2010-06-30

Review 3.  ACP Best Practice No 181: Chemical pathology clinical investigation and management of nephrolithiasis.

Authors:  T M Reynolds
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

4.  Renal stone formation and development.

Authors:  F Grases; O Söhnel; A Costa-Bauzá
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

5.  Effects of an aqueous extract from Phyllantus niruri on calcium oxalate crystallization in vitro.

Authors:  M E Barros; N Schor; M A Boim
Journal:  Urol Res       Date:  2003-01-21

6.  Inhibition of calcium oxalate crystallization by commercial human serum albumin and human urinary albumin isolated from two different race groups: evidence for possible molecular differences.

Authors:  Allen L Rodgers; Priscilla D Mensah; Sylva L Schwager; Edward D Sturrock
Journal:  Urol Res       Date:  2006-12

7.  Involvement of VKORC1 in the inhibition of calcium oxalate crystal formation in HK-2 cells.

Authors:  Bo Hu; Hao-Ran Wu; Zhi-Yong Ma; Zhuan-Chang Wu; Ying-Mei Lu; Guo-Wei Shi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

Review 8.  Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall's plaques.

Authors:  Xue-Ru Wu
Journal:  Urolithiasis       Date:  2014-08-06       Impact factor: 3.436

9.  The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions.

Authors:  John C Lieske; Gerard Farell; Sergio Deganello
Journal:  Urol Res       Date:  2003-12-09

10.  Modulation of calcium oxalate dihydrate growth by selective crystal-face binding of phosphorylated osteopontin and polyaspartate peptide showing occlusion by sectoral (compositional) zoning.

Authors:  Yung-Ching Chien; David L Masica; Jeffrey J Gray; Sarah Nguyen; Hojatollah Vali; Marc D McKee
Journal:  J Biol Chem       Date:  2009-07-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.